摘要
目的研究心脉隆治疗冠心病心力衰竭（心衰）的临床疗效及对血浆高敏C反应蛋白（hs-CRP）和N末端B型钠肽前体（NT-proBNP）的影响。方法本研究纳入2014年10月至2015年10月在我院确诊的84例冠心病心衰的老年患者，将其随机分为对照组（42例）和观察组（42例），对照组采用常规治疗。观察组采用常规治疗联合心脉隆治疗。治疗1周后，比较两组患者治疗前后的Lee氏心衰计分、心功能分级和生活质量评分；比较两组患者治疗前后血浆hs-CRP和NTproBNP的变化，记录两组患者治疗期间的不良反应。结果治疗后观察组心衰的临床疗效为83．3％（35例），高于对照组54．7％（23例）（χ^2=8．016，P=0．033）。观察组心功能的临床疗效为80．9％（34例），高于XCN组59．5％（25例）（χ^2=6．219，P=0．019）。治疗后观察组的生活质量评分为（15．89±3．39）分，低于对照组（23．80±5．66）分（t=7．266，P=0．026）。另外，治疗后两组患者血浆NT-proBNP和hsCRP水平均低于治疗前，且观察组治疗后NT-proBNP和hsCRP水平均低于对照组，分别为（1136．6±236．8）ng／L和（2266．9±260．9）ng／L、（3．06±0．26）mg／L、（3．56±0．29）mg／L（t=6．608、5．106，p=0．019、0．009）。两组患者治疗期间未发生严重不良反应。结论心脉隆能够安全有效地改善冠心病患者的心脏功能，提高患者的生活质量，而且还能阻断动脉粥样硬化的炎性反应。
Objective To investigate the clinical efficacy of Xinmailong on heart failure in coronary heart disease and on the levels of hs-C-reactive protein （hs-CRP）and N-terminal B-type natriuretic peptide （NT-proBNP）. Methods 84 elderly patients diagnosed with heart failure in coronary heart disease were enrolled in this study at our hospital from October 2014 to October 2015. All patients were randomly divided into the control group with conventional treatment（n= 42） and observation group with conventional plus Xinmailong treatment（n： 42）. The Lee＇s heart failure score,cardiac function grade,quality of life score and the changes of plasma hs-CRP and NT proBNP after one week of therapy were compared between the two groups before versus after treatment. The adverse reactions were observed during the treatment. Results The clinical efficacy rate of heart failure after treatment was significantly higher in the observation group （83.3%, 35 cases）than in control group（54.7-, 23 cases） （χ^2=8. 016,P= 0. 033）. The clinical efficacy of heart function after treatment was significantly higher in the observation group（80.9%, 34 cases）than in the control group （59. 5% ,25 cases）（χ^2=6. 219,P：0. 019）. After treatment,the quality of life score was significantly lower in observation group （ 15.89±3.39） than in the control group （23.80±5, 66） （t = 7. 266, P 0. 026）. The plasma levels of NT-proBNP and hs-CRP were significantly lower after than before treatment in NT proBNP[（1 136.6±236.8）ng/L and （2 266.9±260.9）ng/L] ,and in hs-CRP（（3.06±0.26）mg/L and （3.56±0.29）mg/L） （t= 6. 608,5. 106,P=0. 019,0. 009）. There were no serious adverse reactions in both groups during the treatment. Conclusions Xinmailong can not only improve safely and effectively the quality of life of patients, but also block the atherosclerosis of the inflammatory response.
出处
《中华老年医学杂志》
CAS
CSCD
北大核心
2017年第5期502-505,共4页
Chinese Journal of Geriatrics
关键词
心力衰竭
利钠肽
脑
C反应蛋白
Heart failure
Natriuretic peptide,brain
C-reactive protein
